William Blair Issues Optimistic Forecast for TMDX Earnings

TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) - William Blair raised their Q3 2025 earnings estimates for shares of TransMedics Group in a research report issued to clients and investors on Thursday, February 27th. William Blair analyst R. Daniels now expects that the company will post earnings of $0.45 per share for the quarter, up from their previous forecast of $0.43. The consensus estimate for TransMedics Group's current full-year earnings is $1.00 per share. William Blair also issued estimates for TransMedics Group's Q4 2025 earnings at $0.61 EPS, Q3 2026 earnings at $0.59 EPS and Q4 2026 earnings at $0.84 EPS.

TMDX has been the topic of a number of other research reports. Piper Sandler reduced their target price on TransMedics Group from $110.00 to $90.00 and set an "overweight" rating on the stock in a research report on Wednesday, December 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Wednesday, February 5th. TD Cowen lowered their target price on shares of TransMedics Group from $175.00 to $120.00 and set a "buy" rating for the company in a research note on Monday, November 18th. Robert W. Baird reduced their price target on shares of TransMedics Group from $150.00 to $120.00 and set an "outperform" rating on the stock in a research note on Wednesday, December 11th. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $122.70.

TransMedics Group Trading Down 9.2 %

TMDX traded down $6.99 during trading hours on Monday, reaching $69.33. The company's stock had a trading volume of 2,198,104 shares, compared to its average volume of 2,161,526. The stock has a market cap of $2.33 billion, a PE ratio of 73.76 and a beta of 2.12. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The business's 50-day moving average is $67.81 and its 200-day moving average is $100.76.

Institutional Investors Weigh In On TransMedics Group

Large investors have recently modified their holdings of the company. Arizona State Retirement System lifted its stake in TransMedics Group by 1.9% during the fourth quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock worth $603,000 after purchasing an additional 184 shares during the last quarter. Venturi Wealth Management LLC raised its holdings in TransMedics Group by 33.7% during the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company's stock worth $136,000 after purchasing an additional 219 shares in the last quarter. National Bank of Canada FI lifted its position in shares of TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company's stock worth $65,000 after buying an additional 262 shares during the last quarter. Quarry LP boosted its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company's stock valued at $58,000 after buying an additional 312 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its position in shares of TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company's stock valued at $76,000 after buying an additional 316 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.